SS 23 - GU 5: Milestones in Metastatic Prostate Cancer

Presentations

• 03:00pm - 03:10pm PT

  Intermittent Androgen Deprivation Therapy Plus Comprehensive Stereotactic Body Radiotherapy for Hormone Sensitive Oligometastatic Prostate Cancer: Mature Results of a Prospective Trial

  Speaker: Patrick Cheung, MD - Sunnybrook Odette Cancer Centre, Toronto
• 03:00pm - 04:00pm PT

  GU 5: Milestones in Metastatic Prostate Cancer

  Speaker: Abhishek Solanki, MD, MS - Loyola University Medical Center, Maywood
• 03:00pm - 04:00pm PT

  GU 5: Milestones in Metastatic Prostate Cancer

  Speaker: May Abdel-Wahab, MD, PhD, FASTRO - Iaea, Vienna
• 03:10pm - 03:20pm PT

  Local Therapy and Outcome in De Novo Metastatic Prostate Cancer: Individual Patient Data Analysis of the TITAN and ARASENS Trials

  Speaker: Soumyajit Roy, MBBS, MSc. - University Hospitals Seidman Cancer Center, Cleveland
• 03:20pm - 03:30pm PT

  The Role of Stereotactic Body Radiotherapy in Oligoprogressive Prostate Cancer: A Site-Specific Analysis of the Prospective, Phase II RADIANT Trial

  Speaker: Kara Ruicci, MD, PhD - University of Toronto, Toronto
• 03:30pm - 03:40pm PT

  Efficacy of All-Site Radiotherapy at the Hormone-Sensitive Stage in Combination with Systemic Therapy in Grade Group 5 Metastatic Prostate Cancer: Long-Term Data from a Single-Institution

  Speaker: Huizhu Chen, MD - Peking University First Hospital, Beijing
• 03:40pm - 03:45pm PT

  Efficacy and Safety of All-Site Radiation Therapy and Standard of Care Therapy with or without Docetaxel for Hormone-Sensitive High Gleason Score Prostate Cancer: 6-Year Results from a Long-Term Study

  Speaker: Huizhu Chen, MD - Peking University First Hospital, Beijing
• 03:45pm - 03:55pm PT

  Discussant

  Speaker: Comron Hassanzadeh, MD, MPH - MD Anderson Cancer Center, Houston